Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stem cells for Gitelman syndrome
ChiCTR2100047600Phase 3Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jan 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of human umbilical cord mesenchymal stem cells in Gitelman syndrome (GS) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Serum potassium (K+), Serum magnesium (Mg2+) and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Gitelman syndrome (GS)
Beyond the preview
Go deeper on ChiCTR2100047600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047600.